Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database
Abstract Multiple myeloma (MM) remains incurable despite the availability of novel agents. This multi-center retrospective cohort study used the Canadian Myeloma Research Group Database to describe real-world outcomes of patients withanti-CD38 monoclonal antibody (mAb) refractory MM subsequently tre...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2023-12-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-023-00946-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594957721927680 |
|---|---|
| author | A. Visram A. De La Torre D. White J. Su E. Masih-Khan M. Chu V. Jimenez-Zepeda A. McCurdy R. LeBlanc K. Song H. Mian M. Louzada M. Sebag D. Bergstrom J. Stakiw A. Reiman R. Kotb M. Aslam C. Venner R. Kaedbey E. Gul D. Reece |
| author_facet | A. Visram A. De La Torre D. White J. Su E. Masih-Khan M. Chu V. Jimenez-Zepeda A. McCurdy R. LeBlanc K. Song H. Mian M. Louzada M. Sebag D. Bergstrom J. Stakiw A. Reiman R. Kotb M. Aslam C. Venner R. Kaedbey E. Gul D. Reece |
| author_sort | A. Visram |
| collection | DOAJ |
| description | Abstract Multiple myeloma (MM) remains incurable despite the availability of novel agents. This multi-center retrospective cohort study used the Canadian Myeloma Research Group Database to describe real-world outcomes of patients withanti-CD38 monoclonal antibody (mAb) refractory MM subsequently treated with standard of care (SoC) regimens. Patients with triple class refractory (TCR) disease (refractory to a proteasome inhibitor, immunomodulatory drug, and anti-CD38 mAb) were examined as a distinct cohort. Overall, 663 patients had disease progression on anti-CD38 mAb therapy, 466 received further treatment (346 with SoC regimens were included, 120 with investigational agents on clinical trial and were excluded). The median age at initiation of subsequent SoC therapy of 67.9 (range 39.6–89.6) years with a median of 3 prior lines (range 1–9). The median PFS and OS from the start of subsequent therapy was 4.6 (95% CI 4.1–5.6) months and 13.3 (95% CI 10.6–16.6) months, respectively. The median PFS and OS of patients with TCR disease (n = 199) was 4.4 (95% CI 3.6–5.3) months and 10.5 (95% CI 8.5–13.8) months. Our results reinforce that real-world patients with relapsed MM, particularly those with TCR disease, have dismal outcomes. There remains an urgent unmet need for the development of and access to effective therapeutics for these patients. |
| format | Article |
| id | doaj-art-25d073218398474c9d4e1ac87f5798aa |
| institution | Kabale University |
| issn | 2044-5385 |
| language | English |
| publishDate | 2023-12-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Blood Cancer Journal |
| spelling | doaj-art-25d073218398474c9d4e1ac87f5798aa2025-01-19T12:11:01ZengNature Publishing GroupBlood Cancer Journal2044-53852023-12-011311710.1038/s41408-023-00946-zReal world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) DatabaseA. Visram0A. De La Torre1D. White2J. Su3E. Masih-Khan4M. Chu5V. Jimenez-Zepeda6A. McCurdy7R. LeBlanc8K. Song9H. Mian10M. Louzada11M. Sebag12D. Bergstrom13J. Stakiw14A. Reiman15R. Kotb16M. Aslam17C. Venner18R. Kaedbey19E. Gul20D. Reece21Department of Medicine, The Ottawa Hospital, The Ottawa Hospital Research InstituteDivision of Hematology, Dalhousie University and Queen Elizabeth II Health Sciences CentreDivision of Hematology, Dalhousie University and Queen Elizabeth II Health Sciences CentreCanadian Myeloma Research GroupCanadian Myeloma Research GroupDepartment of Oncology, Cross Cancer Institute, Edmonton, AlbertaTom Baker Cancer Center, Department of Hematology, University of CalgaryDepartment of Medicine, The Ottawa Hospital, The Ottawa Hospital Research InstituteHôpital Maisonneuve-Rosemont, Université de MontréalThe Leukemia/Bone Marrow Transplant Program of BC, British Columbia Cancer AgencyJuravinski Cancer Centre (Hamilton-CCO)University of Western Ontario, London Health Sciences CentreDivision of Hematology, McGill University Health CentreDivision of Hematology, Memorial University of Newfoundland, St John’sSaskatoon Cancer CentreOncology, Saint John Regional HospitalMedical Oncology and Hematology, Cancer Care ManitobaAllan Blair Cancer CenterBC Cancer – Vancouver Centre, Lymphoma and Myeloma Program, University of British ColumbiaSegal Cancer Centre, Jewish General Hospital, McGill University, MontrealCanadian Myeloma Research GroupCanadian Myeloma Research GroupAbstract Multiple myeloma (MM) remains incurable despite the availability of novel agents. This multi-center retrospective cohort study used the Canadian Myeloma Research Group Database to describe real-world outcomes of patients withanti-CD38 monoclonal antibody (mAb) refractory MM subsequently treated with standard of care (SoC) regimens. Patients with triple class refractory (TCR) disease (refractory to a proteasome inhibitor, immunomodulatory drug, and anti-CD38 mAb) were examined as a distinct cohort. Overall, 663 patients had disease progression on anti-CD38 mAb therapy, 466 received further treatment (346 with SoC regimens were included, 120 with investigational agents on clinical trial and were excluded). The median age at initiation of subsequent SoC therapy of 67.9 (range 39.6–89.6) years with a median of 3 prior lines (range 1–9). The median PFS and OS from the start of subsequent therapy was 4.6 (95% CI 4.1–5.6) months and 13.3 (95% CI 10.6–16.6) months, respectively. The median PFS and OS of patients with TCR disease (n = 199) was 4.4 (95% CI 3.6–5.3) months and 10.5 (95% CI 8.5–13.8) months. Our results reinforce that real-world patients with relapsed MM, particularly those with TCR disease, have dismal outcomes. There remains an urgent unmet need for the development of and access to effective therapeutics for these patients.https://doi.org/10.1038/s41408-023-00946-z |
| spellingShingle | A. Visram A. De La Torre D. White J. Su E. Masih-Khan M. Chu V. Jimenez-Zepeda A. McCurdy R. LeBlanc K. Song H. Mian M. Louzada M. Sebag D. Bergstrom J. Stakiw A. Reiman R. Kotb M. Aslam C. Venner R. Kaedbey E. Gul D. Reece Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database Blood Cancer Journal |
| title | Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database |
| title_full | Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database |
| title_fullStr | Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database |
| title_full_unstemmed | Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database |
| title_short | Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database |
| title_sort | real world data on outcomes of anti cd38 antibody treated including triple class refractory patients with multiple myeloma a multi institutional report from the canadian myeloma research group cmrg database |
| url | https://doi.org/10.1038/s41408-023-00946-z |
| work_keys_str_mv | AT avisram realworlddataonoutcomesofanticd38antibodytreatedincludingtripleclassrefractorypatientswithmultiplemyelomaamultiinstitutionalreportfromthecanadianmyelomaresearchgroupcmrgdatabase AT adelatorre realworlddataonoutcomesofanticd38antibodytreatedincludingtripleclassrefractorypatientswithmultiplemyelomaamultiinstitutionalreportfromthecanadianmyelomaresearchgroupcmrgdatabase AT dwhite realworlddataonoutcomesofanticd38antibodytreatedincludingtripleclassrefractorypatientswithmultiplemyelomaamultiinstitutionalreportfromthecanadianmyelomaresearchgroupcmrgdatabase AT jsu realworlddataonoutcomesofanticd38antibodytreatedincludingtripleclassrefractorypatientswithmultiplemyelomaamultiinstitutionalreportfromthecanadianmyelomaresearchgroupcmrgdatabase AT emasihkhan realworlddataonoutcomesofanticd38antibodytreatedincludingtripleclassrefractorypatientswithmultiplemyelomaamultiinstitutionalreportfromthecanadianmyelomaresearchgroupcmrgdatabase AT mchu realworlddataonoutcomesofanticd38antibodytreatedincludingtripleclassrefractorypatientswithmultiplemyelomaamultiinstitutionalreportfromthecanadianmyelomaresearchgroupcmrgdatabase AT vjimenezzepeda realworlddataonoutcomesofanticd38antibodytreatedincludingtripleclassrefractorypatientswithmultiplemyelomaamultiinstitutionalreportfromthecanadianmyelomaresearchgroupcmrgdatabase AT amccurdy realworlddataonoutcomesofanticd38antibodytreatedincludingtripleclassrefractorypatientswithmultiplemyelomaamultiinstitutionalreportfromthecanadianmyelomaresearchgroupcmrgdatabase AT rleblanc realworlddataonoutcomesofanticd38antibodytreatedincludingtripleclassrefractorypatientswithmultiplemyelomaamultiinstitutionalreportfromthecanadianmyelomaresearchgroupcmrgdatabase AT ksong realworlddataonoutcomesofanticd38antibodytreatedincludingtripleclassrefractorypatientswithmultiplemyelomaamultiinstitutionalreportfromthecanadianmyelomaresearchgroupcmrgdatabase AT hmian realworlddataonoutcomesofanticd38antibodytreatedincludingtripleclassrefractorypatientswithmultiplemyelomaamultiinstitutionalreportfromthecanadianmyelomaresearchgroupcmrgdatabase AT mlouzada realworlddataonoutcomesofanticd38antibodytreatedincludingtripleclassrefractorypatientswithmultiplemyelomaamultiinstitutionalreportfromthecanadianmyelomaresearchgroupcmrgdatabase AT msebag realworlddataonoutcomesofanticd38antibodytreatedincludingtripleclassrefractorypatientswithmultiplemyelomaamultiinstitutionalreportfromthecanadianmyelomaresearchgroupcmrgdatabase AT dbergstrom realworlddataonoutcomesofanticd38antibodytreatedincludingtripleclassrefractorypatientswithmultiplemyelomaamultiinstitutionalreportfromthecanadianmyelomaresearchgroupcmrgdatabase AT jstakiw realworlddataonoutcomesofanticd38antibodytreatedincludingtripleclassrefractorypatientswithmultiplemyelomaamultiinstitutionalreportfromthecanadianmyelomaresearchgroupcmrgdatabase AT areiman realworlddataonoutcomesofanticd38antibodytreatedincludingtripleclassrefractorypatientswithmultiplemyelomaamultiinstitutionalreportfromthecanadianmyelomaresearchgroupcmrgdatabase AT rkotb realworlddataonoutcomesofanticd38antibodytreatedincludingtripleclassrefractorypatientswithmultiplemyelomaamultiinstitutionalreportfromthecanadianmyelomaresearchgroupcmrgdatabase AT maslam realworlddataonoutcomesofanticd38antibodytreatedincludingtripleclassrefractorypatientswithmultiplemyelomaamultiinstitutionalreportfromthecanadianmyelomaresearchgroupcmrgdatabase AT cvenner realworlddataonoutcomesofanticd38antibodytreatedincludingtripleclassrefractorypatientswithmultiplemyelomaamultiinstitutionalreportfromthecanadianmyelomaresearchgroupcmrgdatabase AT rkaedbey realworlddataonoutcomesofanticd38antibodytreatedincludingtripleclassrefractorypatientswithmultiplemyelomaamultiinstitutionalreportfromthecanadianmyelomaresearchgroupcmrgdatabase AT egul realworlddataonoutcomesofanticd38antibodytreatedincludingtripleclassrefractorypatientswithmultiplemyelomaamultiinstitutionalreportfromthecanadianmyelomaresearchgroupcmrgdatabase AT dreece realworlddataonoutcomesofanticd38antibodytreatedincludingtripleclassrefractorypatientswithmultiplemyelomaamultiinstitutionalreportfromthecanadianmyelomaresearchgroupcmrgdatabase |